ClinicalTrials.gg
RecruitingNCT07560020Updated Oct 22, 2026

A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy

A Phase 2 interventional study of Surlorian and Placebo in Autosomal Dominant RYR1-Related Myopathy, sponsored by RyCarma Therapeutics, Inc.. Recruiting at 9 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by RyCarma Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 5, 2026Site recruiting status changedStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Muscular Diseases with a site in France — 10 open to participants now, 14 under way, 4 of them phase 3. Muscular Diseases · France.

Planned enrollment
19th of 27
28 · median 55
Started
2026
with 2 others
Phase 2
3 of 35
2 open now
Primary completion
2027-08
later than 7 of 13 live
Registered
33rd of 35
by date

Among the 35 studies in Muscular Diseases with a site in France, this one is the 19th largest by planned enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 7 of the 13 other live ones, and was the 33rd registered.

Muscular Diseases

232 studies on the registry are indexed under Muscular Diseases; 54 are open to participants now.

Browse Muscular Diseases studies →

Open to participants now

10 of the 35 studies in Muscular Diseases with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 38 Muscular Diseases studies recruiting now, 21 (55%) set no upper age limit and 10 (26%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Muscular Diseases with a site in France, or all of them as a file.
02

Study summary

This study is testing a medicine called surlorian in adults who have a genetic muscle condition known as autosomal dominant RYR1-related myopathy (RYR1-RM). The goal is to find out whether surlorian improves muscle weakness, and whether it is safe and well tolerated.

Read the detailed description

The study is taking place at several medical centers with doctors who specialize in treating people with RYR1-RM. Everyone in the study will receive both surlorian and a placebo (a "dummy" treatment) at different times, but neither the participants nor the study staff will know which one they are getting during each period.

During Treatment period 1, participants will be randomly assigned to receive either surlorian or a placebo, which will be followed up by a washout period. Following the washout, in Treatment period 2, participants will switch and receive the opposite treatment from what they received in the first period. This main part of the study lasts about 16 weeks.

After finishing the main, placebo-controlled part of the study participants may be able to join an open-label extension lasting approximately 12 months. In this extension, everyone receives surlorian.

03

Conditions studied

  • Autosomal Dominant RYR1-Related Myopathy

Browse trials for

Keywords

  • RYR1-Related Myopathy
  • Adults
  • Phase 2
  • Interventional
  • Surlorian
  • ARM210
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Can understand the written , provides signed and witnessed written informed consent, and agrees to comply with all protocol requirements
  • Confirmed genetic diagnosis of RYR1-RM with autosomal dominant mutation
  • Clinical evidence of weakness affecting any proximal muscle group(s) as assessed by the Investigator
  • Can walk 10 m with or without a cane (no other walking aid allowed)
  • Is either a female of non- or male or female, who agrees to use highly effective /preventive exposure measures from the time of first dose of IP (for a male participant) or the signing of the informed consent form (ICF) (for a female participant) during the trial, and until 7 days after the last dose of IP.

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to understand and comply with protocol requirements or unlikely to complete the study as planned, as judged by the Investigator
  • Any medical condition that, in the opinion of the Investigator, would interfere with the study
  • Females who are pregnant, breastfeeding or intend to become pregnant, or of not using adequate methods
  • Participants with severe pulmonary dysfunction at screening, or evidence of pulmonary exacerbation (defined as an acute worsening of respiratory symptoms that result from a decline in lung function)
  • Cardiac disease by history or at screening that, in the Investigator's opinion, is likely to worsen overall performance of efficacy measures during the study
  • History of seizure disorder, neurologic disease, or neuromuscular disease other than RYR1-RM
  • History of chronic orthopedic issues, acute injury, or expected surgery during the study that may affect the ability to complete study assessments
  • Positive test results at screening for (HIV), surface antigen (HBsAg), or virus (HCV)
  • Participants with screening (ALT) levels >3 × (ULN) or screening aspartate aminotransferase (AST) levels >5 × ULN (isolated elevations of total \<2 × ULN with direct bilirubin below the ULN will be included)
  • History within the past year of alcohol or other drug substance abuse
  • Known to the product of related compounds
  • Treatment with statins, proton pump inhibitors or H2 blockers within 7 days or 5 half-lives, whichever is longer, prior to the first dose of the study drug
  • Treatment with sensitive or narrow therapeutic index substrates within 7 days or 5 half-lives, whichever is longer, prior to first dose of the study drug
  • Treatment with strong or moderate CYP2C8 inhibitor or inducers within 7 days or 5 half-lives, whichever is longer, prior to the first dose of the study drug
  • Currently enrolled in another study or received treatment with any other investigational drug within 30 days or > 5 half-lives, whichever is longer, prior to screening
  • Has reported any suicide ideation of Category 4 or 5 on the C-SSRS within 6 months prior to screening or any suicidal behavior in the last two years prior to screening as indicated by any 'yes' answers on the suicidal behavior section of the C-SSRS
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Group A

    Drug: Surlorian

  • Placebo comparator
    Group B

    Other: Placebo

Interventions

  • 300 mg administered once a day

    Also known as: ARM210 (S48168)

  • OtherPlacebo

    administered once a day

06

What researchers measure

Primary outcomes

  1. Change from baseline in the 1-minute sit-to-stand test (1-MSST)

    Time frame: Day 1 to day 28 [approximately]

Secondary outcomes

  1. Change from baseline in the 6-Minute Walk Test (6-MNWT)

    Time frame: Day 1 to day 28 [approximately]

  2. Change from baseline in the Timed Up and Go Test (TUG)

    Time frame: Day 1 to day 28 [approximately]

  3. Change from baseline in the 4-Stair Climb Test (4-SCT)

    Time frame: Day 1 to day 28 [approximately]

  4. Change from baseline Quantitative Muscle Assessment (QMA)

    Time frame: Day 1 to day 28 [approximately]

  5. Change from baseline Manual Muscle Testing (MMT)

    Time frame: Day 1 to day 28 [approximately]

  6. Change from baseline in Patient-Reported Outcomes Measurement Information System-fatigue (PROMIS-F)

    Time frame: Day 1 to day 28 [approximately]

  7. Change from baseline in Patient-Reported Outcomes Measurement Information System-physical fatigue (PROMIS-PF)

    Time frame: Day 1 to day 28 [approximately]

  8. Chage in International Physical Activity Questionnaire (IPAQ)

    Time frame: Day 1 to day 28 [approximately]

  9. Number of Adverse Events

    Time frame: Day 1 to end of study [approximately 68 weeks]

  10. Change from baseline in systolic blood pressure

    Systolic blood pressure will be measured in millimeters of mercury (mmHg)

    Time frame: Day 1 to end of study [approximately 68 weeks]

  11. Change from baseline in diastolic blood pressure

    Diastolic blood pressure will be measured in millimeters of mercury (mmHg)

    Time frame: Day 1 to end of study [approximately 68 weeks]

  12. Change from baseline in temperature

    Temperature will be measured in degrees Centigrade (°C)

    Time frame: Day 1 to end of study [approximately 68 weeks]

  13. Change from baseline in hemoglobin

    Hemoglobin concentration will be measured in grams per liter (g/L) using standard hematology laboratory methods

    Time frame: Day 1 to end of study [approximately 68 weeks]

  14. Change from baseline in white blood cell count

    White blood cell count will be measured in ×10⁹/L using standard hematology laboratory methods

    Time frame: Day 1 to end of study [approximately 68 weeks]

  15. Change from baseline in platelet count

    Platelet count will be measured in ×10⁹/L using standard hematology laboratory methods

    Time frame: Day 1 to end of study [approximately 68 weeks]

  16. Change from baseline in serum creatinine

    Serum creatinine will be measured in micromoles per liter (µmol/L) using standard clinical chemistry methods

    Time frame: Day 1 to end of study [approximately 68 weeks]

  17. Change from baseline in estimated glomerular filtration rate

    Estimated glomerular filtration rate (eGFR) will be calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration equation

    Time frame: Day 1 to end of study [approximately 68 weeks]

  18. Change from baseline in serum glucose

    Serum glucose concentration will be measured in millimoles per liter (mmol/L) using standard clinical chemistry methods

    Time frame: Day 1 to end of study [approximately 68 weeks]

  19. Change from baseline in QTc interval

    Corrected QT interval (QTcF) will be measured in milliseconds using triplicate 12-lead electrocardiograms

    Time frame: Day 1 to end of study [approximately 68 weeks]

  20. Change from baseline in urine protein

    Urine protein will be measured in milligrams per liter (mg/L) using standard urinalysis methods

    Time frame: Day 1 to end of study [approximately 68 weeks]

07

Study locations

4 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 30, 2026
StartActual
Sep 9, 2026was Jul 2026
Primary completionEst.
Aug 27, 2027
CompletionEst.
Aug 27, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Institut de Myologie - Hôpital de La Pitié-Salpétrière · Paris, FranceNot yet recruiting→Recruiting
  • The Robert Jones and Agnes Hunt Orthopaedic Hospital · Oswestry, United KingdomNot yet recruiting→Recruiting
Oct 5, 2026
Start date
Jul 1, 2026→Sep 9, 2026 (actual)
Oct 5, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • Institut de Myologie - Hôpital de La Pitié-Salpétrière · Paris, FranceContact added e•••@institut-myologie.orgContact added (no phone or email listed)
  • Universitätsklinikum Ulm · Ulm, GermanyContact added n•••@uniklinik-ulm.deContact added (no phone or email listed)
  • Charité - Campus Berlin Buch · Berlin, GermanyContact added m•••@charite.de · •••0507Contact added (no phone or email listed)
  • Radboud Universitair Medisch Centrum · Nijmegen, NetherlandsContact added s•••@radboudumc.nlContact added (no phone or email listed)
  • The Robert Jones and Agnes Hunt Orthopaedic Hospital · Oswestry, United KingdomContact added r•••@nhs.net · •••4142Contact added n•••@nhs.netContact added (no phone or email listed)
  • University College Hospital - PPDS · London, United KingdomContact added L•••@nhs.netContact added (no phone or email listed)
Oct 22, 2026
Show all 2 updates
  1. Oct 22, 2026
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Institut de Myologie - Hôpital de La Pitié-Salpétrière · Paris, FranceContact added e•••@institut-myologie.orgContact added (no phone or email listed)
    • Universitätsklinikum Ulm · Ulm, GermanyContact added n•••@uniklinik-ulm.deContact added (no phone or email listed)
    • Charité - Campus Berlin Buch · Berlin, GermanyContact added m•••@charite.de · •••0507Contact added (no phone or email listed)
    • Radboud Universitair Medisch Centrum · Nijmegen, NetherlandsContact added s•••@radboudumc.nlContact added (no phone or email listed)
    • The Robert Jones and Agnes Hunt Orthopaedic Hospital · Oswestry, United KingdomContact added r•••@nhs.net · •••4142Contact added n•••@nhs.netContact added (no phone or email listed)
    • University College Hospital - PPDS · London, United KingdomContact added L•••@nhs.netContact added (no phone or email listed)
  2. Oct 5, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Institut de Myologie - Hôpital de La Pitié-Salpétrière · Paris, FranceNot yet recruiting→Recruiting
    • The Robert Jones and Agnes Hunt Orthopaedic Hospital · Oswestry, United KingdomNot yet recruiting→Recruiting
    Start date Jul 1, 2026→Sep 9, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07560020
Lead sponsor
RyCarma Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Sep 9, 2026
Primary completion
Aug 27, 2027 (estimated)
Completion
Aug 27, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Patrick Round
Contact
clinicaltrials@rycarma.com
888-209-5458

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Surlorian

Start the discussion